Crestline Management LP Boosts Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

Crestline Management LP raised its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 19.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 105,013 shares of the company’s stock after purchasing an additional 17,317 shares during the quarter. Crestline Management LP’s holdings in Elanco Animal Health were worth $1,272,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Wilmington Savings Fund Society FSB purchased a new position in shares of Elanco Animal Health in the third quarter valued at approximately $35,000. Jones Financial Companies Lllp boosted its position in Elanco Animal Health by 95.6% in the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock valued at $51,000 after buying an additional 2,059 shares during the period. SRS Capital Advisors Inc. increased its position in shares of Elanco Animal Health by 221.2% during the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company’s stock worth $60,000 after acquiring an additional 3,411 shares during the period. MRP Capital Investments LLC acquired a new stake in shares of Elanco Animal Health in the fourth quarter valued at $61,000. Finally, Blue Trust Inc. boosted its holdings in Elanco Animal Health by 47.7% in the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company’s stock valued at $71,000 after purchasing an additional 1,894 shares during the period. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Lawrence Erik Kurzius bought 10,000 shares of the firm’s stock in a transaction on Friday, March 7th. The shares were bought at an average cost of $10.90 per share, for a total transaction of $109,000.00. Following the completion of the transaction, the director now owns 101,459 shares in the company, valued at $1,105,903.10. This trade represents a 10.93 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.89% of the company’s stock.

Elanco Animal Health Trading Up 2.3 %

Shares of Elanco Animal Health stock opened at $12.29 on Friday. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $18.80. The company’s 50-day simple moving average is $9.86 and its 200-day simple moving average is $11.44. The firm has a market cap of $6.10 billion, a price-to-earnings ratio of 30.71, a price-to-earnings-growth ratio of 2.50 and a beta of 1.49. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.31 by $0.06. The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company’s quarterly revenue was down 1.0% compared to the same quarter last year. During the same period last year, the firm earned $0.34 EPS. As a group, equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Morgan Stanley cut their price target on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 26th. Piper Sandler decreased their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday, March 6th. Barclays dropped their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Stifel Nicolaus lifted their price objective on shares of Elanco Animal Health from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, UBS Group cut their price target on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $15.00.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.